After Piper Sandler and Cowen & Co. gave Molina Healthcare (NYSE: MOH) a Buy rating last month, the company received another Buy, this time from Morgan Stanley. Analyst Ricky Goldwasser maintained a Buy rating on Molina Healthcare today and set a price target of $229.00. The company’s shares closed last Friday at $179.15, close to its 52-week high of $187.83.
According to TipRanks.com, Goldwasser is a 5-star analyst with an average return of 9.6% and a 61.3% success rate. Goldwasser covers the Healthcare sector, focusing on stocks such as Quest Diagnostics, 1Life Healthcare, and IQVIA Holdings.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Molina Healthcare with a $194.88 average price target, which is a 10.8% upside from current levels. In a report issued on May 1, Stephens also maintained a Buy rating on the stock with a $202.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $187.83 and a one-year low of $102.85. Currently, Molina Healthcare has an average volume of 795.1K.
Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MOH in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Molina Healthcare, Inc. engages in the provision of health care services. It operates through the Health Plans and Other segments. The Health Plans segment consists of health plans in 11 states and the Commonwealth of Puerto Rico and includes direct delivery business. The Other segment includes the historical results of the MMIS and behavioral health subsidiaries. The company was founded by C. David Molina in 1980 and is headquartered in Long Beach, CA.
